TORONTO (February 13, 2017): QD Solar, a Canadian technology company created by MaRS Innovation and the University of Toronto, announced today the closing of a C$2.5M Series A funding led by DSM Venturing, with matching investment participation from existing investors, MaRS innovation and KAUST Innovation Fund.
The development of this technology is also supported by project funding that was announced in March 2016 from Sustainable Development Technology Canada (SDTC) through a C$2.5M grant, and through the generous support of the Ontario Research ...
Toronto, Canada and Hamburg, Germany, 17 January 2017:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP (“Fibrocor”), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. The company was launched with CDN $ 2.8 m (approx. $ 2.1 m) financing, which includes cash from MaRS Innovation. Evotec will provide all drug discovery activities and will also receive an equity stake.
Fibrocor takes a new approach to understanding and ...
Today MaRS Innovation (MI) and the Korea Health Industry Development Institute (KHIDI) signed a five year global partnership agreement to commercialize the latest advances in biomedical and healthcare innovations which is expected to generate new startups worth over $100M.
This agreement will promote the co-development and commercialization of medical technologies and therapeutics between Ontario and South Korea in concert with industry and government. It will provide the resources to develop and implement novel technological solutions for today’s most urgent healthcare problems and ...
Agreement signed as part of Ontario's life sciences trade mission to Israel
TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for 15 of Toronto's top academic institutions.
Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members to identify in-licensing, co-development or other ...
BlueDot, a Canadian company that helps decision-makers prepare for and response to infectious disease outbreaks, was profiled in the Toronto Star for their work in tracking the Zika virus.
The company, founded by Dr. Kamran Khan, was spun-off from St. Michael's Hospital in partnership with MaRS Innovation. The company raised a Series A with Horzions Ventures in 2015.
Here's an excerpt from Kate Allen's article:
Wayne Gretzky may be an unlikely inspiration for an infectious disease researcher. Yet here Dr. Kamran Khan is, on ...
BresoTec, formerly known as ApneaDx, also among top five finalists
TORONTO, August 11, 2015 – Legworks' next-generation prosthetic knee took first place in Ontario Centres of Excellence’s (OCE’s) Parapan Am Games-affiliated Accessibility Tech Pitch competition. The company immediately said it would use the $20,000 award to fit 200 amputees in developing countries with its device.
Legworks was selected from 18 participants in a two-day elimination pitch competition – one of the features of the Government of Ontario’s Accessibility Innovation Showcase held at MaRS ...
MI's Fazila Seker also interviewed in National Post article on what prompts medical researchers to consider crowdfunding
The WaveCheck crowdfunding campaign, which raised $53,390 on Indiegogo to support clinical trials for a clinical technique invented by researchers at Sunnybrook Health Sciences Centre and Ryerson University, was included in a new Canadian-led study on the merits of crowdfunding to support cancer and rare diseases.
"Crowdfunding drug development: The state of play in oncology and rare diseases," was published in Drug Discovery Today's June issue.
OICR's catalyst grant enables WaveCheck to open first partner site at MD Anderson Cancer Center in May
TORONTO, April 8, 2014 -- People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR).
The funding builds upon MaRS Innovation's Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide in two months last ...
MaRS Innovation's Dr. Fazila Seker and Elizabeth Monier-Williams spoke with Deanna Pogorelc of MedCity News about how to define success for campaigns crowdfunding for technologies and research related to the medical field.
The article, in MedCity News' Hot Topics section, questions whether a crowdfunding campaign needs to reach its funding goal to be deemed successful.
Seker and Monier-Williams completed an Indiegogo crowdfunding campaign in December for WaveCheck, a clinical technique developed to let women and men know if their breast cancer chemotherapy is working ...
Bedside Clinical Systems' (BCS) flagship product, the Bedside Paediatric Warning System or BedSidePEWS™, was covered in the February 2014 edition of Hospital News.
The article, written by Rajesh Sharma who is president and CMO of BCS, explains how the technology helps decrease the amount of code blues in paediatric patients.
Invented by Dr. Christopher Parshuram of the Hospital of Sick Children (SickKids), Bedside PEWS™ is now in three hospitals in Canada, the United States and New Zealand. The technology received FDA approval last year.
Here's an excerpt ...